Centaurus Financial Inc. Takes Position in Hologic, Inc. (NASDAQ:HOLX)

Centaurus Financial Inc. bought a new position in shares of Hologic, Inc. (NASDAQ:HOLX) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 5,564 shares of the medical equipment provider’s stock, valued at approximately $453,000.

Other hedge funds have also added to or reduced their stakes in the company. Prentiss Smith & Co. Inc. lifted its holdings in shares of Hologic by 0.3% during the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock worth $3,967,000 after buying an additional 130 shares in the last quarter. Covestor Ltd increased its position in Hologic by 23.8% during the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after acquiring an additional 133 shares during the period. First Horizon Advisors Inc. raised its stake in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares in the last quarter. Massmutual Trust Co. FSB ADV grew its position in shares of Hologic by 20.3% during the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 831 shares of the medical equipment provider’s stock worth $62,000 after purchasing an additional 140 shares in the last quarter. Finally, Empirical Finance LLC increased its holdings in shares of Hologic by 1.8% during the third quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock worth $690,000 after purchasing an additional 147 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on HOLX. Citigroup cut Hologic from a “buy” rating to a “neutral” rating and cut their price target for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Needham & Company LLC reissued a “buy” rating and set a $90.00 target price on shares of Hologic in a report on Tuesday, October 15th. Mizuho dropped their price target on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. UBS Group increased their price objective on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Finally, Raymond James boosted their target price on shares of Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Hologic has an average rating of “Moderate Buy” and a consensus target price of $89.91.

Hologic Stock Performance

NASDAQ HOLX opened at $79.00 on Wednesday. The firm’s fifty day moving average price is $80.38 and its two-hundred day moving average price is $78.38. The stock has a market cap of $18.35 billion, a PE ratio of 23.72, a PEG ratio of 2.49 and a beta of 0.98. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. Hologic, Inc. has a fifty-two week low of $67.59 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. Hologic’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.89 EPS. On average, equities analysts expect that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.